Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 20/20 | 1.00 |
| ▸ | ITGAV | P06756 | 20/20 | 1.00 |
| ▸ | ITGA2B | P08514 | 6/20 | 1.00 |
| ▸ | ITGB6 | P18564 | 1/20 | 0.51 |
| ▸ | ITGB1 | P05556 | 9/20 | 0.47 |
| ▸ | ITGA5 | P08648 | 8/20 | 0.47 |
| ▸ | ITGB5 | P18084 | 4/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29899937 | 1.00 | ITGB3 (1.00) | ITGB3ITGAVITGA2BITGB6ITGB1 | |
| SCHEMBL244675 | 1.00 | ITGB3 (1.00) | ITGB3ITGAVITGA2BITGB6ITGB1 | |
| SCHEMBL538331 | 1.00 | ITGB3 (1.00) | ITGB3ITGAVITGA2BITGB6ITGB1 | |
| SCHEMBL14182037 | 0.93 | ITGB3 (0.87) | ITGB3ITGAVITGA2BITGB6ITGB1 | |
| SCHEMBL14182014 | 0.90 | ITGB3 (0.82) | ITGB3ITGAVITGA2BITGB6ITGB1 | |
| SCHEMBL14212733 | 0.90 | ITGB3 (0.81) | ITGB3ITGAVITGA2BITGB6ITGB1 | |
| SCHEMBL14212735 | 0.90 | ITGB3 (0.81) | ITGB3ITGAVITGA2BITGB6ITGB1 | |
| SCHEMBL14212732 | 0.90 | ITGB3 (0.81) | ITGB3ITGAVITGA2BITGB6ITGB1 | |
| SCHEMBL6418750 | 0.88 | ITGB3 (0.79) | ITGB3ITGAVITGA2BITGB6ITGB1 | |
| SCHEMBL6419002 | 0.88 | ITGB3 (0.79) | ITGB3ITGAVITGA2BITGB6ITGB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 85 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4637731-A1 | COMBINATION THERAPY FOR TREATING CANCER | GILEAD SCIENCES, INC. (US) | 2025-10-29 | — | — | EP | claimed |
| CN-118497109-A | Method for maintaining and improving stem cell multipotency based on integrin antagonists or inhibitors | 东北大学 | 2024-08-16 | — | — | CN | claimed |
| WO-2024137442-A1 | COMBINATION THERAPY FOR TREATING CANCER | GILEAD SCIENCES, INC. (US) | 2024-06-27 | — | — | WO | claimed |
| US-20220370545-A1 | INTEGRIN RECEPTOR ALPHA V BETA 3 AND ITS LIGAND INVOLVED IN CHRONIC ITCH | NORTH CAROLINA STATE UNIVERSITY | 2022-11-24 | — | — | US | claimed |
| US-20260144674-A1 | Apparatus and Methods for Drug Delivery Using Microneedles | CLEARSIDE BIOMEDICAL, INC. (US) | 2026-05-28 | — | — | US | disclosed |
| US-20260014139-A1 | Femtosecond Laser Treatment Methods | PEYMAN GHOLAM A (US) | 2026-01-15 | — | — | US | disclosed |
| US-12479805-B2 | Indazole hydrazide compound and application thereof | BEIJING BAHEAL CHENGCHUANG PHARMACEUTICAL RESEARCH AND DEVELOPMENT CO., LTD. (CN) | 2025-11-25 | — | — | US | disclosed |
| US-20250345206-A1 | APPARATUS AND METHODS FOR OCULAR INJECTION | CLEARSIDE BIOMEDICAL, INC. (US) | 2025-11-13 | — | — | US | disclosed |
| EP-4637731-A1 | COMBINATION THERAPY FOR TREATING CANCER | GILEAD SCIENCES, INC. (US) | 2025-10-29 | — | — | EP | disclosed |
| EP-4615869-A1 | COMBINATION THERAPY COMPRISING BISPECIFIC ANTIBODIES COMPRISING AN NRP1 BINDING DOMAIN | Pinetree Therapeutics, Inc. (US) | 2025-09-17 | — | — | EP | disclosed |
| US-12350261-B2 | Methods and devices for the treatment of ocular diseases in human subjects | CLEARSIDE BIOMEDICAL, INC. (US) | 2025-07-08 | — | — | US | disclosed |
| US-20250186253-A1 | DEVICES AND METHODS FOR ADJUSTING THE INSERTION DEPTH OF A NEEDLE FOR MEDICAMENT DELIVERY | CLEARSIDE BIOMEDICAL, INC. (US) | 2025-06-12 | — | — | US | disclosed |
| US-20220273196-A1 | INGESTIBLE DEVICE AND ASSOCIATED METHODS | GLAS USA LLC | 2022-09-01 | — | — | US | disclosed |
| WO-2022170822-A1 | INDAZOLE HYDRAZIDE COMPOUND AND APPLICATION THEREOF | 北京大学第一医院 | 2022-08-18 | — | — | WO | disclosed |
| US-20220249814-A1 | METHODS AND DEVICES FOR TREATING A DISEASE WITH BIOTHERAPEUTICS | GLAS USA LLC | 2022-08-11 | — | — | US | disclosed |
| WO-2022157336-A1 | TREATMENT OF CORONAVIRUS | ROYAL COLLEGE OF SURGEONS IN IRELAND (IE) | 2022-07-28 | — | — | WO | disclosed |
| US-20220202933-A1 | Method Of Treating, Reducing, Or Alleviating A Medical Condition In A Patient | PEYMAN GHOLAM A (US) | 2022-06-30 | — | — | US | disclosed |
| US-20220175714-A1 | USE OF RIVASTIGMINE IN PREPARATION OF ANTI-RADIATION MEDICAMENT | SOOCHOW UNIVERSITY (CN) | 2022-06-09 | — | — | US | disclosed |
| CN-114366749-A | Application of integrin inhibitor in preparation of medicine for treating kidney cancer | 中国人民解放军海军军医大学 | 2022-04-19 | — | — | CN | disclosed |
| WO-2022076938-A1 | APPARATUS AND METHODS OF RETINAL INJECTION | CLEARSIDE BIOMEDICAL, INC. (US) | 2022-04-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260014139-A1 | Femtosecond Laser Treatment Methods | GSK3B, GSK3A, CTNND1 | ITGB3 41/4885ITGAV 270/4885ITGA2B 269/4885 |
| US-20260144674-A1 | Apparatus and Methods for Drug Delivery Using Microneedles | PROKR2, SLC10A2, GLP1R | ITGB3 263/4885ITGAV 69/4885ITGA2B 403/4885 |
| US-12479805-B2 | Indazole hydrazide compound and application thereof | ITGB3, AR, HDAC3 | ITGB3 1/4885ITGAV 12/4885ITGA2B 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.